What is the total value and structure of Merck's acquisition of Bio-Techne, and what are the key financial terms?

Merck agreed to acquire Bio-Techne for $11.3 billion in an all-cash transaction, with a per-share offer price of $73 — representing a 36% premium over Bio-Techne’s one-month volume-weighted average price and a 24% increase over its prior trading day’s closing price. The deal, approved by both companies’ boards, is expected to close between late 2026 and early 2027, pending shareholder approval and regulatory clearances across multiple jurisdictions.

How does this acquisition align with Merck’s strategic goals in the life sciences sector, and what capabilities does Bio-Techne bring?

According to Merck CEO Kai Beckmann, the acquisition is a core part of the company’s long-term expansion in life sciences, driven by strong product-line complementarity — particularly in high-growth areas including multi-omics, spatial transcriptomics, and raw materials for cell and gene therapies. Bio-Techne, headquartered in Minneapolis, specializes in specialty reagents, antibodies, spatial biology instruments, and clinical diagnostic kits, serving global research institutions and pharmaceutical companies; its 2025 fiscal year revenue exceeded $1.2 billion, and it operates 34 offices and 15 manufacturing sites across North America, Europe, and Asia-Pacific. The deal specifically addresses Merck’s gap in high-end antibody offerings — a market valued globally at $40 billion — and Bio-Techne will continue operating as an independent business unit post-acquisition.

Merck Agrees to Acquire Bio-Techne for $11.3 Billion

Jun 29, 2026

Merck has agreed to acquire US life sciences firm Bio-Techne for $11.3 billion to bolster its portfolio in antibodies and cell therapy materials, with completion expected by 2027.

ccin

2026-03-25

Merck to Buy Terns in $6.7 Billion Deal

2026-06-29

Merck Agrees to Acquire Bio-Techne for $11.3 Billion

Merck Agrees to Acquire Bio-Techne for $11.3 Billion

FAQ